Free Newsletter
Antidepressants show upside in economic downturn
Free newsletter via e-mail
Tools
Antidepressants are looking to be big-time recession-busters. In spite of the cost of brand-name meds, Eli Lilly's Cymbalta has grown by leaps and bounds during the economic downturn, with second-quarter sales up by 14 percent year-over-year. And antidepressants in general haven't halted their upward trend, posting $9.6 billion in 2008 sales, up from $9.4 billion in 2007, on 164 million scrips, up from 160 million. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
